What is DMAA (1,3-Dimethylamylamine)?

DMAA (known chemically as 1,3-dimethylamylamine, Methylhexanamine, Forthane, or 4-methylhexan-2-amine) is a simple aliphatic alkylamine compound featuring a six-carbon branched chain structure. Originally developed in the 1940s as a synthetic nasal vasoconstrictor, DMAA functions as an indirect sympathomimetic agent that mimics catecholamine activity within cellular and vascular tissue models. Unlike aromatic amphetamine derivatives, DMAA lacks a central benzene ring, operating primarily through aliphatic adrenergic receptor engagement and central monoamine transporter inhibition.

Formulated and analytical batch-tested for Modern Aminos, DMAA is supplied as a high-purity reference aqueous solution with a concentration of 50MG/mL for laboratory screening. Researchers investigating catecholamine release, alpha-adrenergic signaling, and comparative monoaminergic pathways frequently utilize DMAA alongside alternative neuro-chemical reference standards. For instance, evaluating Fladrafinil’s allows laboratories to contrast selective central DAT inhibition against the peripheral adrenergic vasopressor cascades characteristic of aliphatic alkylamines.

Chemical and Molecular Data

Compound Name	DMAA (1,3-Dimethylamylamine)
Format & Packaging	Analytical-Grade Reference Powder / Sealed Glass Reagent Vial
Synonyms / Alt Names	Methylhexanamine, 1,3-DMAA, 4-methylhexan-2-amine, Forthane, Geranamine
CAS Number	105-41-9 (Free Base) \| 13803-74-2 (HCl Salt)
Chemical Formula	C₇H₁₇N
Molecular Weight	115.22 g/mol
IUPAC Name	4-methylhexan-2-amine
InChIKey	SQGYOAMRGKWBAC-UHFFFAOYSA-N
SMILES Code	`CCC(C)CC(C)N`

What are the Mechanisms of Action?

The biochemical pathways and cellular targets of DMAA in laboratory research include:

Indirect Sympathomimetic Catecholamine Release: Research demonstrates that DMAA acts as a substrate for presynaptic monoamine transporters, facilitating the localized release of endogenous norepinephrine (noradrenaline) into synaptic cleft models. This indirect sympathomimetic mechanism triggers downstream adrenergic cascade signaling in isolated tissue preparations.
Alpha-1 and Alpha-2 Adrenergic Receptor Engagement: In vascular smooth muscle assays, DMAA exhibits affinity for alpha-1 (α₁) and alpha-2 (α₂) adrenergic receptors. Receptor binding stimulates intracellular calcium mobilization, resulting in marked vasoconstriction and elevated perfusion pressure in isolated organ tissue models.
Norepinephrine & Dopamine Transporter (NET / DAT) Reuptake Inhibition: In vitro radioligand binding assays confirm that DMAA weakly inhibits the reuptake of norepinephrine and dopamine via human monoamine transporters. This dual action extends synaptic neurotransmitter residence times in neuronal cell culture assays.

What do Preclinical & Pharmacological Assays Show for DMAA?

When evaluating research efficacy and published scientific literature for DMAA (1,3-dimethylamylamine):

Sympathomimetic & Vascular Pharmacodynamics: Classical and modern pharmacological studies cataloged in ScienceDirect evaluate the pressor responses and receptor kinetics of aliphatic alkylamines. Experimental data demonstrate that 4-methylhexan-2-amine produces dose-dependent vascular smooth muscle contraction and transient elevations in vascular resistance in animal tissue assays.
Chemical Profiling & Mass Spectrometry Data: Official structural characterization cataloged on PubChem documents the nuclear magnetic resonance (NMR) spectrum, gas chromatography-mass spectrometry (GC-MS) fragmentation patterns, and salt solubility parameters of 1,3-dimethylamylamine for analytical reference verification.
Comparative Monoamine Transporter Binding Assays: Competitive binding studies in cell lines expressing recombinant human NET and DAT receptors confirm that while DMAA exhibits sympathomimetic activity, its affinity for monoamine transporters is significantly lower than that of classical catecholaminergic compounds, operating primarily via indirect displaced release mechanics.

How does DMAA compare to other compounds?

To evaluate chemical structures, sympathomimetic potency, and monoamine selectivity, researchers compare DMAA against alternative central nervous system modulators and nootropic reference compounds available at Modern Aminos:

Compound / Reference	Chemical Class	Core Mechanism of Action	Research Focus & Profile
DMAA (1,3-Dimethylamylamine)	Aliphatic Alkylamine	Indirect norepinephrine release, alpha-adrenergic stimulation, and weak NET/DAT inhibition	Focuses on peripheral vascular vasoconstriction, adrenergic signaling, and sympathomimetic tissue assays
Fladrafinil	Bis-Fluorinated Modafinil Analog	Selective dopamine transporter (DAT) inhibition and central histamine elevation	Focuses on targeted central wakefulness and cognitive alertness; provides a balanced monoaminergic model without acute peripheral adrenergic vasoconstriction
Phenylpiracetam Hydrazide	Phenylated Racetam Derivative	Modulates nicotinic acetylcholine receptors (nAChRs) and inhibits DAT reuptake	Focuses on rapid central cognitive stimulation, acetylcholine pathway sensitivity, and physical cold-resistance models
Bromantane	Adamantane Actoprotector	Upregulates Tyrosine Hydroxylase (TH) gene expression to drive de novo dopamine synthesis	Focuses on non-depleting dopamine production, physical endurance, and non-sedating GABAergic anxiolysis

Frequently Asked Questions (FAQs)

1. What is the structural classification of DMAA?

DMAA (1,3-dimethylamylamine / 4-methylhexan-2-amine) is an aliphatic alkylamine. Unlike aromatic central nervous system stimulants, DMAA possesses a saturated seven-carbon branched alkyl chain with an amine group at position 2, lacking any phenyl or aromatic ring structures.

2. How does DMAA exert its sympathomimetic effects in laboratory assays?

DMAA operates primarily as an indirect sympathomimetic agent. In presynaptic nerve terminal models, it promotes the displacement and release of stored norepinephrine into the synaptic cleft, where the neurotransmitter activates postsynaptic alpha-1 and alpha-2 adrenergic receptors.

3. What are the solubility parameters of DMAA reference powder?

DMAA hydrochloride salt is readily soluble in polar solvents, including water, ethanol, and dimethyl sulfoxide (DMSO). For cell culture or tissue bath assays, reference solutions should be freshly prepared using sterile laboratory buffers or ultra-pure water to ensure exact concentration accuracy.

4. How does DMAA research differ from Fladrafinil research?

DMAA is an aliphatic sympathomimetic that causes pronounced peripheral vascular smooth muscle contraction via adrenergic release. In contrast, Fladrafinil is a centrally selective dopamine reuptake inhibitor that modulates wakefulness pathways without inducing acute peripheral vasopressor spikes.

5. What are the compliance and storage guidelines for DMAA at Modern Aminos?

DMAA provided by Modern Aminos is strictly for laboratory, in vitro, and analytical research use only (RUO). It is not for human or animal consumption. Reagent vials should be stored tightly sealed in a cool, dry environment (15°C to 25°C) protected from humidity and heat.

The products offered by Modern Aminos are intended strictly for laboratory research purposes only and are sold exclusively to qualified professionals, institutions, and entities. These products are not for human consumption, veterinary use, or any other application involving living organisms, including but not limited to diagnostic, therapeutic, or recreational purposes.

By purchasing this product, you confirm that:

You are a qualified professional or entity with the necessary knowledge, training, and facilities to handle chemical reagents safely and appropriately.
You will use this product in full compliance with all applicable local, state, and federal laws and regulations.

Prohibited Uses

This product is not to be used as an active pharmaceutical ingredient (API) in compounding or manufacturing drugs for human or veterinary use.
It is strictly prohibited to use this product for administration to humans or animals under any circumstances.
Modern Aminos does not condone or permit the use of its products for the development, testing, or production of illegal substances.

Regulatory Compliance

Modern Aminos does not claim that this product is approved by the U.S. Food and Drug Administration (FDA) for any purpose. The statements regarding this product have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

Liability Statement

The buyer assumes full responsibility for ensuring the safe handling, storage, and use of this product. Modern Aminos is not liable for any damages, direct or indirect, resulting from improper handling, storage, or unauthorized use of this product. Furthermore, Modern Aminos reserves the right to refuse sales to any individual or entity suspected of misusing its products.

If you have questions about the safe and lawful use of this product, consult a qualified professional with expertise in laboratory research. By proceeding with this purchase, you agree to these terms and conditions.

DMAA 50MG/ML

DMAA 50MG/ML